CYLD and hepatocellular carcinoma: In the present study, the clinicopathological relevance of the deubiquitinase CYLD was assessed in a series of 95 human hepatocellular carcinoma (HCC) samples, obtained from patients undergoing resection or liver transplantation as treatment of early stage HCC.